Hol dir die App Get the App
⭐️⭐️⭐️⭐️⭐️
44 Bewertungen
Zur App
DAX 26.122,00 0,58% Dow Jones 53.312,00 1,00% MDAX 32.022,90 1,03% Nikkei 225 65.907,20 0,58% S&P 500 7.680,13 0,46% STOXX Europe 50 6.458,50 0,58% Nasdaq 100 29.328,40 0,37% Bitcoin 77.507,31 USD 6,72% Gold 148,05 USD 1,86% EUR/USD 1,17 USD 0,04%
DAX 26.122,00 0,58% Dow Jones 53.312,00 1,00% MDAX 32.022,90 1,03% Nikkei 225 65.907,20 0,58% S&P 500 7.680,13 0,46% STOXX Europe 50 6.458,50 0,58% Nasdaq 100 29.328,40 0,37% Bitcoin 77.507,31 USD 6,72% Gold 148,05 USD 1,86% EUR/USD 1,17 USD 0,04%
+49 (0) 172 414 333 6
Wertpapiere

Aktie US7310942070

PolarityTE, Inc.

0,11 €

  • 0,00 €
  • |
  • 0,00 %

Your browser does not support the canvas element.

  • Juli
  • Aug.
  • 0.11
  • 0.12

ERTRÄGE

Das Unternehmen zahlt regelmäßig eine Dividende von 85,20 € pro Aktie mit einer Rendite von 76.759,91% – sehr hoch – könnte auf Bewertungsrabatt oder Risiken hindeuten. Die Ausschüttungsquote von 0,00% ist nicht vorhanden. Die Dividende ist stabil und unverändert – das Unternehmen hält verlässlich.

85,20 €

Jährliche Dividende

76.759,91 %

Rendite

  • 42,63 €

    Jan.

0,00 %

Dividenden-Wachstum

  • 16

0,00 %

Ausschüttungsquote

  • 100 %

    G

  • 100 %

    OCF

Historische Dividenden

    • 26,08 %
    • 42,63 €
    Jan. 16
    • 0,00 %
    • 0,00 €
    Feb. 16
    • 0,00 %
    • 0,00 €
    März 16
    • 0,00 %
    • 0,00 €
    Apr. 16
    • 0,00 %
    • 0,00 €
    Mai 16
    • 0,00 %
    • 0,00 €
    Juni 16
    • 0,00 %
    • 0,00 €
    Juli 16
    • 0,00 %
    • 0,00 €
    Aug. 16
    • 0,00 %
    • 0,00 €
    Sept. 16
    • 0,00 %
    • 0,00 €
    Okt. 16
    • 0,00 %
    • 0,00 €
    Nov. 16
    • 0,00 %
    • 0,00 €
    Dez. 16

UNTERNEHMEN

73.000,0 $

Umsatz

  • 17,4 Mio.

    NG

  • 10,5 Mio.

    F&E

  • -10,3 Mio.

    BG

  • 73.000,00

    U

-91,03 %

Umsatz-Wachstum

  • 22

  • 23

  • 24

  • 25

  • 26

17,4 Mio. $

Nettogewinn

  • 105,5 %

    ROE
  • 23.845,2 %

    ROS
  • 76,5 %

    ROA
  • -36.723,3 %

    GPM

-21,6 Mio. $

Operativer Cashflow

  • FCF

    100 %
  • -0 %

    CapEx

16,5 Mio. $

Eigenkapital

  • EK 73 %
  • 27 % FK

42

Mitarbeiter

  • 1.738,1 $

    Umsatz / MA
  • 414.452,4 $

    Gewinn / MA

KGV

0,22 $

KBV

0,24 $

KCV

-0,18 $

KUV

54,83 $

EV/EBITDA

0,12 $

EV/EBIT

0,18 $

EV/FCF

0,15 $

EV/Umsatz

-45,89 $

EnterpriseValue

-3,3 Mio. $

Eigenkapitalrendite

105,45 %

Umsatzrendite

23.845,21 %

EBIT-Marge

-25.071,23 %

EBITDA-Marge

-36.723,29 %

Kapitalumschlag

0,003 $

Gesamtkapitalrendite

76,45 %

Eigenkapitalquote

0,73 $

Fremdkapitalquote

0,27 $

Verschuldungsgrad

0,38 $

Dyn. Verschuldungsgrad

-0,29 $

Sachinvestitionsquote

0,002 $

Anlagendeckungsgrad 1

0,42 $

Anlagendeckungsgrad 2

0,34 $

Liquidität 1. Grades

5,16 $

Liquidität 2. Grades

5,16 $

Liquidität 3. Grades

6,03 $

Dividende pro Aktie

0,00 $

Dividendenrendite

0,00 %

Ausschüttungsquote

0,00 %

Buchwert pro Aktie

2,39 $

Cashflow pro Aktie

-3,13 $
Stand: 31.03.2023 TTM

Fakten

  • Sitz

    USA

  • Hauptsitz

    Salt Lake City

  • Börsengang

    16.08.1999

  • Ausstehende Aktien

    6,91 Mio.

  • Mitarbeiter

    42

  • Währung

    USD

  • Sektor

    Gesundheitswesen

  • Industrie

    Biotechnology

  • Börse

    NASDAQ

  • Ticker

    PTE

  • Webseite

    polarityte.com

Aktie

Unternehmensinfos

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.